Catalog No.
RHD68304
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
RBTNL1, Rhombotin-2, T-cell translocation protein 2, LMO-2, Cysteine-rich protein TTG-2, TTG2, LIM domain only protein 2, LMO2, RHOM2, RBTN2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P25791
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3G86
Single-cell profiling reveals monocyte heterogeneity and association with liver fibrosis in patients with chronic HBV., PMID:40227083
The LIM-domain-only protein LMO2 and its binding partner LDB1 are differentially required for class switch recombination., PMID:39847321
Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance., PMID:39374535
[Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores]., PMID:37356936
Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels., PMID:36358737
Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004
A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2., PMID:33837087
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds., PMID:33794223
Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System., PMID:32187599
The life and death of the germinal center., PMID:31751845
Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model., PMID:30962539
KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas., PMID:29140403
Littoral cell angioma of the spleen: a study of 25 cases with confirmation of frequent association with visceral malignancies., PMID:27374010
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP., PMID:27196819
Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles., PMID:26869285
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study., PMID:26071053
The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma., PMID:25701230
Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions., PMID:24881582
Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex., PMID:24407558
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients., PMID:24117687
Tissue microarray in a subset of South African patients with DLBCL., PMID:23942329
High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas., PMID:22776842
Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody., PMID:22394247
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era., PMID:22066713
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation., PMID:22009820
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy., PMID:21441466
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab., PMID:21135273
Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain., PMID:20980262
Evaluation of an enzyme-linked fluorescent assay for the detection of Listeria monocytogenes from food., PMID:20938093
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study., PMID:19786664
V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia., PMID:19455608
Selection of complementary single-variable domains for building monoclonal antibodies to native proteins., PMID:19208637
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab., PMID:18615101
An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions., PMID:18438427
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab., PMID:18086797
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas., PMID:17038524
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy., PMID:16864781
The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells., PMID:9707419
The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development., PMID:8033210
For research use only. Not for human or drug use.
